What the programme actually adds
Supervised care for fibromyalgia, an exercise add-on tested against sham, home pulmonary rehabilitation, walking after spinal-cord injury and the findings a nerve test cannot settle alone.
In a six-month fibromyalgia trial, exercise arrived through live online classes. Participants could switch between morning and afternoon groups, report symptoms during a session and receive changes to the movements. Recorded make-up sessions were available. The intervention was a programme with supervision and several treatment components. Understanding that whole package is essential to interpreting what improved.
Today's reading room follows that question across rehabilitation: what did the programme add, what was measured, and what can the result tell an individual? A sham-controlled back-pain trial tests an extra device against the same exercise programme. A pulmonary study tests whether a home service can run successfully. Spinal-cord and nerve studies examine the limits of categories and forecasts. A limb-loss survey brings satisfaction, body image and participation into view.
All 88 registered sources and 15 study domains were checked. Discovery returned 806 article records and one book record; 173 article records were newly retrieved compared with the last published October 11 scan. Newly retrieved includes older publications. All 12 inaccessible sources were retried without recovery. Two main research reports were read in full; four research summaries use primary abstracts, including one subscription preview. The new chapter's primary abstract, actual safety notices, established guidance and course descriptions were checked separately.
A supervised programme with a measurable effect—and important boundaries
Researchers randomized 68 adults with fibromyalgia to six months of home telerehabilitation or usual care: 35 versus 33. The programme offered three 50–60-minute sessions weekly, combining Pilates-based exercise, self-myofascial release, low-load resistance exercise, stretching and relaxation. Progression and modifications depended on symptoms and tolerance. The control group continued usual routines and medication without adding a new structured exercise programme.
The primary measure was the Revised Fibromyalgia Impact Questionnaire (FIQR), a 0–100 scale covering function, overall impact and symptoms; lower scores indicate less burden. At six months, the unadjusted mean difference between groups favored the programme by −11.81 points, 95% confidence interval (CI) −19.61 to −4.02. Primary questionnaire data were available for all 68 participants. The result supports a benefit of the package compared with this control condition.
The size of benefit deserves care. The authors used an 8.1-point difference when planning sample size, but that value came from the original FIQ, not an established universal FIQR threshold. The confidence interval also includes effects smaller than 8.1 points. An average difference does not establish that every participant experienced an important change.
Adherence was 87.5%, averaging 63 of 72 scheduled sessions. That combined observed attendance at live sessions with participants' written confirmation of recorded make-up sessions. No adverse or serious adverse events were reported. This was a selected, predominantly female sample with the digital access needed to participate; it does not establish the same benefit, access or safety for every person with fibromyalgia.
For patients, the useful questions concern supervision, symptom adjustments, time demands and which outcomes will be followed. The study cannot identify whether Pilates, self-myofascial release, clinician contact or the remote delivery format supplied the benefit individually.
Clinical notes: primary data, missing mood questionnaires and different statistical questions
The FIQR and sleep questionnaire data were complete. The Depression Anxiety Stress Scales had missing responses only in the intervention arm: eight at three months and thirteen at six months. Longitudinal mood analyses therefore used 22 intervention participants and all 33 controls. That selective non-response may bias mood results even though the primary outcome is complete.
The review of the actual tables also matters for sleep. The authors reported a significant difference in trajectories over time, but the six-month sleep-score difference was −0.89, 95% CI −2.63 to +0.85. These analyses answer different questions. A favorable time pattern does not establish a clear between-group difference at the final visit or normal sleep. Anxiety showed no significant group-by-time effect.
Participants and the intervention provider could not be blinded; outcomes were self-reported. Coding the arms during analysis does not remove expectation or attention effects during treatment. Recruitment through online support groups and a sample that was 97.1% female limit transferability. The Greek FIQR adaptation had an unpublished pilot psychometric evaluation.
Registration occurred retrospectively in August 2026, after data collection ended in August 2025. A public full protocol and separate statistical analysis plan were unavailable. This limits independent confirmation of prospective outcome and analysis choices. There was no follow-up after the programme ended, and no comparison isolating its components or testing cost-effectiveness. The main PDF was read through disclosures; the supplementary flow figure and original cited studies were not audited.
Primary fibromyalgia trial record · Publisher page and full PDF · DOI: 10.2340/jrm.v58.46786
Test the additional treatment against the same exercise
A trial randomized 148 adults aged 18–65 with chronic nonspecific low-back pain, 74 per group, to active photobiomodulation plus motor-control exercise or sham photobiomodulation plus the same exercise. Photobiomodulation uses light as a therapeutic intervention. Both groups received twelve sessions over six weeks.
At six weeks, the primary pain difference was −0.4 points on a 0–10 scale, 95% CI −1.2 to +0.4. Disability differed by −0.7 points on the 0–24 Roland–Morris questionnaire, 95% CI −2.4 to +0.9. Lower scores favor the active add-on, but both intervals cross zero. The authors concluded that it supplied no clinically important additional improvement in this setting.
Between-group differences remained negligible through twelve months, and no treatment-related adverse events were reported. The abstract describes concealed allocation, intention-to-treat analysis and blinding of participants, therapists and assessors. Full methods and detailed follow-up information remained inaccessible after publisher retries.
A patient considering an extra treatment can ask how much it adds to the care already being received. Improvement within both groups would not identify a benefit of the active device. This trial addresses the add-on; it does not isolate the effect of exercise against no exercise.
Clinical notes: uncertainty does not mean equivalence
A confidence interval crossing zero leaves uncertainty about the direction of an effect. It does not by itself establish exact equivalence. Here the estimates, their intervals and the authors' clinical interpretation support limited added benefit for the tested regimen. Detailed clinical-importance thresholds and a prespecified equivalence margin were not available in the abstract; no independent equivalence claim is made.
Circulating prostaglandin E2 differed by +31 pg/mL, 95% CI −4 to +66 at six weeks. This biomarker finding does not establish a mechanism for a patient-important benefit. Device parameters, adherence, missing-data procedures and complete harms tables were not appraised. Redirect pages were not counted as full-text access.
Primary photobiomodulation trial abstract · DOI: 10.1016/j.jphys.2026.09.005
An app can be workable before its clinical effectiveness is established
A single-centre study evaluated a home pulmonary rehabilitation service for people with COPD, using connected devices and an application. One phase included 20 participants to test transmission of heart rate, oxygen-saturation and daily-step data. A second phase included 20 participants in an eight-week home programme. These are phase-specific counts; the abstract does not establish forty distinct participants.
Agreement between locally stored and transmitted values was at least 99% for the reported data. In the programme phase, 19 of 20 participants completed rehabilitation. Median satisfaction was 30 on the Client Satisfaction Questionnaire-8, and median usability was 80 on the System Usability Scale.
Exercise endurance increased: the median paired difference on a constant-work-rate test was +171 seconds, 95% CI +17 to +725. That wide interval comes from a before-and-after comparison. There was no randomized concurrent control demonstrating how much change was caused by this service.
For patients, reliable data transfer, a usable interface and support for completing a programme matter. They are promising delivery findings. They do not establish equivalence to centre-based rehabilitation, lower hospitalization risk or a benefit of one device over another.
Clinical notes: transmission agreement and treatment effect
Agreement between transmitted and locally stored data is not the same as proving that a device measures the physiological quantity accurately against an independent standard. The abstract's technical endpoint answers whether the readings traveled consistently.
Retention, satisfaction and usability address feasibility. Endurance was exploratory. In an uncontrolled programme, repeated testing, other care and changes over time can contribute to improvement. The confidence interval describes uncertainty in the observed change, not protection against those alternative explanations. Detailed eligibility, harms procedures and complete full-text analyses remained unavailable; the authors call for randomized evaluation.
Primary pulmonary telerehabilitation feasibility abstract · DOI: 10.1016/j.apmr.2026.10.001
A group outcome gives context for a personal goal
Researchers examined 1,209 people with traumatic spinal-cord injury in the Rick Hansen registry across thirty Canadian trauma and rehabilitation centres. Their outcome was outdoor walking at twelve months, classified as dependent, limited or independent community ambulation. This is a more specific question than whether someone can take steps during an examination.
In the baseline ASIA Impairment Scale (AIS) neurological severity categories, the proportions achieving independent community ambulation were 1.6% for grade A, 12% for B, 28% for C and 65% for D. In grade D, 24% had limited community ambulation and 11% were in the dependent category. The reported proportions are rounded.
Lower-extremity motor scores, age and injury mechanism helped describe additional groupings, with relevant factors differing by AIS grade. The authors propose descriptive charts based on observed outcomes. These findings are useful context, but a group proportion is not a guaranteed individual probability or an instruction to abandon a walking goal.
Clinical notes: neurological classification and community performance
Neurological impairment, performance in a supervised setting and community mobility are different constructs. A baseline injury category does not supply every detail of a person's later participation or assistance needs. This observational cohort cannot determine the effect of a specific rehabilitation treatment.
Full methods, charts, outcome definitions, handling of missing follow-up and any separate validation were not available in the subscription preview. Those details matter before applying the proportions to an individual whose circumstances may differ from the cohort. The abstract reports associations used to describe phenotypes; no independently validated prediction tool was appraised.
Primary spinal-cord ambulation cohort abstract · Publisher abstract and access boundary · DOI: 10.1038/s41393-026-01281-3
A demyelinating-looking nerve test does not settle the cause
A two-centre French study examined 63 patients with biopsy-confirmed definite or probable vasculitic neuropathy. Vasculitis involves inflammation of blood vessels; nerve-conduction studies measure aspects of electrical signaling along nerves. Clinical records and tests from 2014–2020 were reviewed retrospectively.
Twenty-seven patients (42.9%) had nerve-conduction abnormalities suggestive of demyelination, and eleven (17.5%) met the EAN/PNS electrophysiological criteria for demyelination used when evaluating suspected chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Conduction block was the most common such abnormality, followed by prolonged F-wave latency.
All patients had pain and sensory disturbances; 73% had motor deficits. A symmetrical distal polyneuropathy was the predominant pattern, present in 26 patients. The study is a reminder that electrical patterns need to be interpreted alongside the history, examination and other evidence. Meeting an electrophysiological component of criteria is not the same as establishing a complete CIDP diagnosis.
Clinical notes: a selected cohort is not a diagnostic-accuracy study
The participants were already selected for biopsy-confirmed vasculitic neuropathy. These percentages do not estimate how often vasculitis occurs among all patients with demyelinating test findings, and they do not supply the sensitivity or specificity of a diagnostic strategy.
The abstract contains subgroup percentages whose wording does not clearly distinguish any demyelinating abnormality from fulfillment of formal criteria. Those subgroup figures are omitted here. The overall counts are explicit. Detailed nerve-test thresholds, biopsy-selection procedures and full analyses were unavailable after retries. No recommendation to biopsy every patient, or to change treatment from an electrical pattern alone, follows from this report.
Primary vasculitic-neuropathy cohort abstract · DOI: 10.1002/mus.70434
Ask what the prosthesis—and the care—needs to support
An exploratory U.S. survey included 229 adults with major lower-limb loss: 130 women and 99 men. Participants came from civilian, Veterans Affairs and Department of Defense settings. They were at least one year after limb loss and could complete the English-language survey. Recruitment and data collection occurred in 2019–2022.
Women reported lower aesthetic and functional satisfaction, poorer body image and social adjustment, and higher anxiety than men. For example, the unadjusted mean anxiety T-scores were 53.6 versus 49.4, a calculated descriptive difference of 4.2 points. Those raw means are not an adjusted treatment effect or a diagnosis of an anxiety disorder.
The researchers used regression models accounting for age, general health, cause of limb loss and time since loss. They did not detect gender differences in several other domains, including depression, activity restriction and healthcare needs. Undetected differences do not establish equivalence.
For a person using a prosthesis, the study supports a wider conversation about appearance, comfort in social settings, body image and functional satisfaction. Group findings should guide questions rather than assumptions about any individual's preferences.
Clinical notes: representation, missing responses and multiple outcomes
Of 374 eligible people proceeding to the survey, 229 completed it; reasons for non-completion were not collected. Responses were generally optional, and available-case analyses used different numbers for different outcomes. Height and weight response rates were only 23% and 28%, preventing adjustment for body mass index.
This was a convenience sample, with limited racial and ethnic diversity and English-only participation. Gender was self-reported. Many outcomes were tested without a multiple-comparison adjustment; Bayesian modeling of bounded scores does not remove that concern. Findings remain exploratory and may reflect residual confounding or broader life experiences as well as limb-loss-related needs.
The main text, narrative results and limitations were read. Detailed regression supplements and table/figure images were not independently appraised; adjusted numerical estimates are not reproduced here. The study does not demonstrate that any particular device, fitting approach or gender-specific treatment changes these outcomes.
Primary limb-loss needs-assessment record · Main full report · DOI: 10.1371/journal.pone.0359172
A new reference for a rare developmental disorder
The new UBA5-related neurodevelopmental disorder entry describes developmental impairment with possible axial hypotonia, limb hypertonia or spasticity, seizures, movement disorders, visual problems and feeding difficulties. Its primary abstract states that diagnosis involves compatible findings and disease-causing variants in both copies of UBA5.
The summary describes coordinated developmental, neurological, feeding, rehabilitation and family support. This is a reference synthesis, not a trial of a new treatment, and the features overlap with other conditions. The chapter's own indexed abstract and contribution date were read; the full chapter and detailed management tables were not retrieved. Individual diagnosis and genetic counseling require the clinical team.
A care plan begins with the person and the pain diagnosis
NICE recommends a person-centred assessment of all chronic pain, including how it affects daily activities, sleep, relationships and wellbeing. It advises discussing priorities, abilities, goals, benefits, risks and uncertainty. Normal or negative test findings should be communicated without invalidating the person's pain experience.
For chronic primary pain in people aged sixteen and over, it recommends supervised group exercise adapted to needs, preferences and abilities, and consideration of acceptance and commitment therapy or cognitive behavioural therapy for pain with appropriately trained professionals. Condition-specific guidance applies when an underlying condition accounts for the pain and its impact. Primary and secondary pain can coexist.
This is established guidance, not a new October announcement or a blanket rule for every chronic-pain diagnosis. Actual recommendations 1.1 and 1.2.1–1.2.3 were checked; underlying evidence reviews were not appraised.
Two equipment checks with different actions
Medline procedure kits—Class I classification updated October 13. FDA's updated communication says the affected products and recommendations are unchanged. Certain kits containing recalled BD ChloraPrep applicators may have fungal contamination. The implicated applicators are ChloraPrep Clear 1 mL, item 930480/lot 4032183, and FREPP Clear 1.5 mL with paper lidding, item 930299/lot 4073005.
For the specifically affected kits, the notice instructs inventory review and quarantine, then destruction of the entire kit after response forms are completed. Old over-labels directing removal of one component are insufficient for these identified kits. Applicator identifiers do not replace checking the complete affected-kit list; that attachment was not independently appraised. No serious injuries or deaths had been reported to Medline as of August 17, not as a newly verified October count.
Actual FDA Medline kit recall and inventory list
Philips Lumify—early alert current October 9. Unexpected transducer re-registration can prevent scanning until network access is available; connection instability may also interrupt use. FDA advises use where Wi-Fi or cellular signals are readily accessible unless a backup ultrasound device is immediately available, and maintaining backup devices or modalities for care.
The notice lists affected iOS and Android versions and customer instructions. Philips reported eight serious injuries and four deaths associated with the issue as of September 29. Associated reports do not establish causation for every event or a risk rate. This is an early alert; the page does not say a software fix has already been released. Images were not independently reviewed.
Bring methods questions to the journal club
AAPM&R's October journal club is listed for October 19, 7:30–8:30 p.m. Central, with registration required and eligibility for Academy members. The description lists papers on autonomic symptoms and vascular endothelial function after spinal-cord injury, and adverse events with knee PRP injections. It offers no credit. The actual course description was read; neither the session nor those papers was appraised for this edition.
The Academy's October 13 brain–computer-interface grand-rounds description outlines implantable device approaches, patient candidacy and the rehabilitation care pathway. It is a course description, not proof of treatment benefit. The lecture, recording and transcript were not reviewed, and this article confers no CME.
Actual October journal-club description · Actual BCI course description
Which result answers the treatment-effect question?
A home rehabilitation feasibility study reports reliable transmission, 95% programme completion and a favorable before-and-after endurance change. There is no randomized concurrent control. Which interpretation is best supported?
- The app is proved equivalent to centre-based rehabilitation.
- The endurance confidence interval eliminates confounding.
- The service appears workable in the selected sample, while a causal endurance benefit remains unestablished.
- Reliable transmission proves the physiological accuracy of every sensor.
Reveal the answer and reasoning
C. Technical performance and retention support feasibility. A before-and-after change can include other care, repeated testing and changes over time. A confidence interval quantifies sampling uncertainty in the estimate; it does not create a missing control group. Agreement between transmitted and stored readings also differs from validation against an independent physiological standard.
A short glossary for the reading room
- Telerehabilitation
- Rehabilitation delivered remotely. Its content, supervision, equipment and support can vary considerably.
- Multicomponent programme
- A package with several treatment elements. Studying the package does not isolate the contribution of each element.
- Mean difference and confidence interval
- The average difference between groups and a range expressing uncertainty under the statistical analysis. Neither guarantees an individual's result.
- Group-by-time interaction
- A test of whether groups change differently across time. It differs from comparing them at one final visit.
- Complete-case analysis
- An analysis using participants with the required data. Selective missing responses can affect which people remain represented.
- Sham control
- A comparison designed to resemble an intervention while withholding its proposed active component.
- Feasibility study
- A study of whether a service or research procedure can be delivered and evaluated. It may collect exploratory outcomes without establishing effectiveness.
- Community ambulation
- Walking in community settings. The amount of assistance or limitation matters, as well as whether walking is possible.
- Demyelinating features
- Nerve-test patterns suggestive of problems involving myelin, the insulating layer around nerve fibres. The pattern alone does not identify its cause.
- Convenience sample
- Participants recruited through available channels rather than probability sampling. Their experiences may differ from the wider population.
References & the coverage record
- Six-month supervised telerehabilitation combining pilates-based therapeutic exercise and self-myofascial release in adults with fibromyalgia: a randomized controlled trial. Journal of rehabilitation medicine · PMID 42867081 · DOI 10.2340/jrm.v58.46786
- Photobiomodulation therapy has a negligible effect as an adjunct to motor control exercise in people with chronic non-specific low back pain: a randomised trial. Journal of physiotherapy · PMID 42864195 · DOI 10.1016/j.jphys.2026.09.005
- Technical and clinical feasibility of a pulmonary telerehabilitation model for people with COPD. Archives of physical medicine and rehabilitation · PMID 42863686 · DOI 10.1016/j.apmr.2026.10.001
- Characterizing ambulation potential following acute traumatic spinal cord injury: a populational cohort study on 1209 patients. Spinal cord · PMID 42860442 · DOI 10.1038/s41393-026-01281-3
- Electrophysiologic Demyelinating Features Are Common in Vasculitic Neuropathy: A Cohort of Biopsy-Confirmed Cases. Muscle & nerve · PMID 42864260 · DOI 10.1002/mus.70434
- Quantifying the unique needs of women with lower limb loss: A national, cross-sectional, survey-based needs assessment. PloS one · PMID 42862871 · DOI 10.1371/journal.pone.0359172
Six research reports were appraised: two randomized trials, a two-phase pulmonary feasibility study, two retrospective cohorts and a cross-sectional limb-loss needs assessment. The complete main fibromyalgia PDF, including methods, Tables I–V, results, discussion, limitations and disclosures was read; methods and outcome tables were visually checked on rendered pages. Its separate supplementary flow figure, registry entry, raw data and underlying references were not independently appraised. The limb-loss report main methods, narrative results, discussion, limitations and disclosures were read; detailed regression supplements and table/figure images were not appraised. Low-back photobiomodulation, COPD telerehabilitation and vasculitic neuropathy use primary abstracts after publisher retries failed or returned redirect stubs. The spinal-cord ambulation report uses its primary abstract and subscription preview; full methods and charts remained unavailable. A new UBA5-related neurodevelopmental disorder GeneReviews chapter was read through its own PubMed BookDocument abstract and contribution date, not its underlying references; the full chapter was not retrieved. Actual NICE NG193 recommendations 1.1 and 1.2.1–1.2.3 were checked as established April 2021 guidance, not the underlying evidence reviews. Actual FDA Medline convenience-kit and Philips Lumify communications were read. The Medline Class I classification was updated October 13 while product recommendations were unchanged; the complete kit inventory attachment and device images were not appraised. Actual AAPM&R BCI and October journal-club course descriptions and an ASIA 2027 registration announcement were inspected; lectures, recordings and paid content were not reviewed. Twelve inaccessible registered sources were retried without recovery; ATS landing access recovered in the initial scan compared with October 11. Discovery retrieved 806 journal-article metadata records plus one book record; 173 article records were newly retrieved against the October 11 edition. Capped search changes are not publication dates or retractions. No October 12 edition was present in the inspected archive. No physician review has been recorded. This edition grants no CME and its study question is not official examination material.
The discovery window was 2026/09/13–2026/10/13. A journal index check can miss work not yet indexed. A retrieved landing page does not verify every linked publication, paid course, podcast or textbook chapter. Candidate counts are discovery records, not validated practice changes.
See every registered source and its status → · Download this edition’s machine-readable coverage record
Educational, not medical advice. Discuss treatment choices with your clinician. Sources and evidence evolve; each dated edition preserves what was checked for that issue.